Xeomin demonstrated comparable to Botox Cosmetic
A prospective, multicenter, randomized, double blinded, parallel trial, XEOMIN® and BOTOX® subjects were randomized 1:1. The study enrolled 250 healthy female patients (≥18 years old) with glabellar lines of at least moderate severity at maximum frown. 122 subjects were treated with 20 Units of XEOMIN; 128 subjects were treated with 20 Units of BOTOX in a single treatment cycle. Patients were classified as responders only. If they had a ≥ 1 point improvement from the baseline on the Facial Wrinkle Scale (FWS) at maximum frown, as assessed by the independent review panel using subject photographs at one month post treatment.1-3
In two randomized, double blinded, multicenter, clinical trials, Xeomin was clinically proven to temporarily improve the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.1-3
1. XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use. Prescribing Information. Merz Pharmaceuticals, LLC, 2015. 2. Carruthers A, Carruthers J, Heinz M, et al. Multicentre, randomized phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg 2013;39:551–558. 3. Hanke CW, Narins RS, Brandt F, et al. A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint. Dermatol Surg. 2013;39(6):891-899. 4. Botox® Cosmetic (onabotulinumtoxinA) for injection. Prescribing Information. Allergan, Inc. 2016. 5. Dysport® (abobotulinumtoxinA). Prescribing Information. Medicis Pharmaceutical Corporation. 2015. 6. Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins. In: Jankovic botulinum toxin therapeutic and clinical practice and science. Saunders Elsevier 2009. 7. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers’ product summaries. J Clin Pharm and Therapeutics. 2007;32:387-402. 8. Aoki KR. Preclinical update on Botox® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol.1999;6:S3-S10. 9. Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®/Dysport®/Azzalure®, and XEOMIN®/Bocouture®. Drug R D. 2010;10:67-73. 10. Kane MA, et al. (2015). Dermatol Surg 41(11):1319.